Prostate Cancer - Results from #21400

A method to estimate composite doses for organs at risk in prostate cancer patients treated with EBRT in combination with HDR BT - Abstract February 22, 2014

Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: A systematic review and meta-analysis - Abstract February 22, 2014

Surgical quality is more than volume: The association between changing urologists and complications for patients with localized prostate cancer - Abstract February 22, 2014

Statins: Protectors or pretenders in prostate cancer? - Abstract February 22, 2014

Dietary lycopene, angiogenesis, and prostate cancer: A prospective study in the prostate-specific antigen era - Abstract February 22, 2014

Generation of "virtual" control groups for single arm prostate cancer adjuvant trials - Abstract February 22, 2014

Prostate cancer nomograms: A review of their use in cancer detection and treatment - Abstract February 21, 2014

Identification of men with the highest risk of early disease recurrence after radical prostatectomy - Abstract February 21, 2014

The prostate cancer risk stratification project: Database construction and risk stratification outcome analysis - Abstract February 21, 2014

Patient reported outcome measure (PROM) of quality of life after prostatectomy - Results from a 5-year study - Abstract February 21, 2014

Prospective comparison of the impact of robotic-assisted laparoscopic radical prostatectomy versus open radical prostatectomy on health-related quality of life and decision regret - Abstract February 21, 2014

What is the clinical significance of FDG unexpected uptake in the prostate in patients undergoing PET/CT for other malignancies? - Abstract February 21, 2014

A simple reconstruction of the posterior aspect of rhabdosphincter and sparing of puboprostatic collar reduces the time to early continence after laparoscopic radical prostatectomy - Abstract February 21, 2014

Can single positive core prostate cancer at biopsy be considered a low-risk disease after radical prostatectomy? - Abstract February 21, 2014

Metastatic castration-resistant prostate cancer (CRPC): Preclinical and clinical evidence for the sequential use of novel therapeutics - Abstract February 21, 2014

Enzalutamide (Xtandi) for patients with metastatic, resistant prostate cancer - Abstract February 21, 2014

Role of endorectal MR imaging and MR spectroscopic imaging in defining treatable intraprostatic tumor foci in prostate cancer: Quantitative analysis of imaging contour compared to whole-mount histopathology - Abstract February 19, 2014

Oral etoposide and oral prednisone for the treatment of castration resistant prostate cancer - Abstract February 19, 2014

Less satisfaction with information in patients with prostate cancer treated with surgery and salvage radiotherapy compared with patients treated with curative radiotherapy alone, despite similar health-related quality of life - Abstract February 19, 2014

Detection of the index tumor and tumor volume in prostate cancer using T2w and DW MRI alone - Abstract February 19, 2014

Page 1071 of 1447